mixedAnecdotalMay 3, 2026
Experience variability
PT-141 public discussion is highly experience-driven, with recurring themes around response variability and side-effect tolerance.
Reddit / searchlow confidencereddit
Source PT-141 (Bremelanotide)
Bremelanotide · Vyleesi
Sexual HealthApprovedApprovedPrescriptionSubQIntranasal
Popular for:Sexual dysfunction, FDA-approved for HSDD, melanocortin agonist
10
Registered Trials
16
Trial Publications
107
PubMed References
Approved
Evidence Level
Overview
PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist that is FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. The short version: people usually care about it for sexual dysfunction, fda-approved for hsdd, melanocortin agonist, but the strength of the evidence depends heavily on indication and study type.
PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist that is FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the only FDA-approved peptide that works through the central nervous system to address sexual dysfunction.
Originally derived from Melanotan II research, PT-141 was developed after researchers noticed sexual arousal effects during tanning peptide trials. Unlike PDE5 inhibitors (Viagra, Cialis) which work on blood flow, PT-141 acts on the brain's melanocortin system to influence desire and arousal.
Research Snapshot
What the evidence says
ApprovedPT-141 (Bremelanotide) currently shows 10 registered trials from ClinicalTrials.gov, 16 PubMed trial publications (14 RCT-tagged), and 107 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.
Known vs uncertain
Known signals
- 10 registered trials are tracked from ClinicalTrials.gov intervention records.
- 16 PubMed clinical-trial publications are indexed.
- 14 PubMed randomized controlled trial publications are indexed.
- 107 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.
Open questions
- Evidence strength may vary by indication, route, formulation, and population.
- Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
- Regulatory status and compounding access can change independently from the research literature.
Mechanism of Action
PT-141 activates melanocortin receptors MC3R and MC4R in the hypothalamus, the brain region that regulates sexual behavior and arousal.
Key Research Benefits
FDA-approved for HSDD in premenopausal women (Vyleesi)
Works through CNS melanocortin pathways (not vascular)
Studied for both male and female sexual dysfunction
Only peptide FDA-approved for sexual function
Does not require sexual stimulation to take effect
Clinical Evidence Summary
Research Pipeline
Preclinical
Animal
Phase I
Phase II
Phase III
Approved
10
Registered Trials
16
Trial Publications
14
RCT Publications
107
PubMed References
ClinicalTrials.govPubMed ESearchCurated alias queryChecked May 3, 2026
Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.
10
Registered trials
16
Trial publications
14
RCT publications
107
PubMed references
52
Reviews
3
Meta-analyses
Registered trials source
Jun 1, 2026
Bremelanotide, PT-141
Uses curated ClinicalTrials.gov intervention aliases to avoid misleading registry matches.
View sourcePublication counts source
May 3, 2026
PT-141, Bremelanotide, Vyleesi
Uses PT-141 and approved drug-name aliases instead of the parenthetical display label.
View sourceFDA-approved as Vyleesi (2019) for HSDD in premenopausal women. Available via prescription. Also available as research compound.
Key PubMed References
107 PubMed references · showing top 23 by relevance
View all on PubMedFemale Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder.
Review
Borland JM, Kohut-Jackson AL, Peyla AC, et al. · Neuropharmacology · 2025
PMID: 39793696Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma CellsSuppression of Survivin Expression.
In Vitro
Suzuki S, Kitanaka C, Okada M · Anticancer research · 2024
PMID: 39197897Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.
Human Study
Spielmans GI, Ellefson EM · Journal of sex research · 2024
PMID: 36809187An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.
Human Study
Cipriani S, Alfaroli C, Maseroli E, et al. · Expert opinion on pharmacotherapy · 2023
PMID: 36242769Targeting the central melanocortin system for the treatment of metabolic disorders.
Review
Sweeney P, Gimenez LE, Hernandez CC, et al. · Nature reviews. Endocrinology · 2023
PMID: 37365323Anecdotes & Sentiment
Public discussion, not clinical evidence
This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.
Side Effects & Safety
- Nausea (most common, ~40% in trials) - Facial flushing - Headache - Injection site reactions - Transient blood pressure elevation
Nausea (most common, ~40% in trials)
Facial flushing
Headache
Injection site reactions
Transient blood pressure elevation
Known Interactions
No curated interaction entry is live for PT-141 (Bremelanotide) yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Comparison Pages
Comparison pages
AllNo comparison page is linked yet.
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.